title: In vivo characterization of A-192411: a novel fungicidal lipopeptide (II).
abstract: The ability of the novel antifungal cyclic hexalipopetide A-192411 to treat fungal infections in rodents is presented. Efficacy was demonstrated against Candida albicans as both prolonged survival of systemically infected mice and clearance of viable yeasts from kidneys. The efficacy of A-192411, administered intraperitoneally, was equivalent to amphotercin B at a 4-fold lower dose by weight in the systemic candidiasis models in mice, while the efficacy of A-192441 administered intravenously was equivalent to amphotercin B by weight in the Candida pyelonephritis model in rats. A-192411 also slightly prolonged the survival of immunocompromised mice infected systemically with Aspergillus fumigatus.
authors.affiliation: Infectious Diseases Research, Pharmaceutical Products Division, Abbott Laboratories, Abbott Park, IL 60064, USA. ybennani@athersys.com
authors.forename: Jonathan A
authors.initials: JA
authors.lastname: Meulbroek
authors.forename: Angela M
authors.initials: AM
authors.lastname: Nilius
authors.forename: Qun
authors.initials: Q
authors.lastname: Li
authors.forename: Weibo
authors.initials: W
authors.lastname: Wang
authors.forename: Lisa
authors.initials: L
authors.lastname: Hasvold
authors.forename: Beth
authors.initials: B
authors.lastname: Steiner
authors.forename: Daniel A
authors.initials: DA
authors.lastname: Dickman
authors.forename: Hong
authors.initials: H
authors.lastname: Ding
authors.forename: David
authors.initials: D
authors.lastname: Frost
authors.forename: Robert C
authors.initials: RC
authors.lastname: Goldman
authors.forename: Paul
authors.initials: P
authors.lastname: Lartey
authors.forename: Jacob J
authors.initials: JJ
authors.lastname: Plattner
authors.forename: Youssef L
authors.initials: YL
authors.lastname: Bennani
mesh_terms: D000666:Amphotericin B / Q000627:therapeutic use; D000818:Animals; D000935:Antifungal Agents / Q000627:therapeutic use*; D001228:Aspergillosis / Q000188:drug therapy* / Q000382:microbiology; D001232:Aspergillus fumigatus; D002176:Candida albicans; D002177:Candidiasis / Q000188:drug therapy* / Q000382:microbiology; D025141:Drug Resistance, Fungal; D016867:Immunocompromised Host; D007668:Kidney / Q000187:drug effects / Q000382:microbiology; D051379:Mice; D009842:Oligopeptides / Q000138:chemical synthesis* / Q000494:pharmacology*; D051381:Rats; D016019:Survival Analysis
chemical_list: C476327:A-192411; D000935:Antifungal Agents; D009842:Oligopeptides; D000666:Amphotericin B